Can Johnson & Johnson’s oral Icotyde compete with biologics in psoriatic arthritis?
Icotyde achieved 58% ACR20 in Phase 3 psoriatic arthritis, but the 400 mg dose added no benefit. Can Johnson & Johnson challenge biologics?
Pharma & Biotech